Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial-Reference-Cited by-同舟云学术

Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial

Published:2023-12 Issue:10419 Volume:402 Page:2295-2306
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Chu Quincy,Perrone Francesco,Greillier Laurent,Tu Wei,Piccirillo Maria Carmela,Grosso Federica,Lo Russo Giuseppe,Florescu Marie,Mencoboni Manlio,Morabito Alessandro,Cecere Fabiana Letizia,Ceresoli Giovanni Luca,Dawe David E,Zucali Paolo Andrea,Pagano Maria,Goffin John R,Sanchez Myriam Locatelli,Gridelli Cesare,Zalcman Gerard,Quantin Xavier,Westeel Virginie,Gargiulo Piera,Delfanti Sara,Tu Dongsheng,Lee Christopher W,Leighl Natasha,Sederias Joana,Brown-Walker Pamela,Luo Yiwen,Lantuejoul Sylvie,Tsao Ming-Sound,Scherpereel Arnaud,Bradbury Penelope,Laurie Scott A,Seymour Lesley

Funder

Merck

Canadian Cancer Society

Publisher

Elsevier BV

Subject

General Medicine

Reference26 articles.

1. The worldwide pandemic of asbestos-related diseases;Stayner;Annu Rev Public Health,2013

2. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma;Vogelzang;J Clin Oncol,2003

3. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial;Zalcman;Lancet,2016

4. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial;Baas;Lancet,2021

5. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer;Gandhi;N Engl J Med,2018

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Malignant pleural mesothelioma: The disdained member of thoracic oncology!;World Journal of Experimental Medicine;2024-09-20

2. Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma;Lung Cancer;2024-09

3. Nichtresezierbares Pleuramesotheliom: Wenig Vorteile für Antiangiogenese plus Immuntherapie;Deutsches Ärzteblatt Online;2024-08-23

4. New Treatment for Pleural Mesothelioma;Haigan;2024-08-20

5. Treatment patterns and humanistic burden of malignant pleural mesothelioma in Spain;Clinical and Translational Oncology;2024-07-06